Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Peritoneal Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 109Cyclophosphamide 89fludarabine 70Carboplatin 57Injections 56Bevacizumab 49Specimen Handling 43Gemcitabine 41Magnetic Resonance Spectroscopy 40Paclitaxel 39Nivolumab 38venetoclax 36Dexamethasone 35Cisplatin 34Biopsy 34Temozolomide 31Docetaxel 29Capecitabine 27atezolizumab 26Oxaliplatin 26Fluorouracil 26Pemetrexed 24Irinotecan 24Azacitidine 24abemaciclib 23toripalimab 22Fulvestrant 22fludarabine phosphate 21Rituximab 21Leucovorin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × LY-2157299 × Clear all
NCT05700656 2024-07-22

Galunisertib Combined With Capecitabine in Advanced CRC With PM

The Netherlands Cancer Institute

Phase 1/2 Recruiting
31 enrolled
GastrointestinalGynecologic

Peritoneal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡